checkmate-743 study in mesothelioma
Published 4 years ago • 1.1K plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
3:33
immunotherapy for mesothelioma
-
4:06
mesothelioma: how will novel immunotherapies impact surgery?
-
1:49
1l treatment in mesothelioma: optimizing treatments for individual patients
-
2:03
thoughts on the rames study in mesothelioma
-
1:27
managing epithelial mesothelioma
-
1:34
the need for rcts in immunotherapy for mesothelioma
-
3:34
role of immunotherapy in the management of mesothelioma
-
4:44
confirm trial: nivolumab in relapsed malignant mesothelioma
-
2:12
atomic-meso: pegargiminase in malignant pleural mesothelioma
-
0:50
checkpoint inhibition in mesothelioma: the confirm trial
-
2:58
updates in treating mesothelioma
-
1:27
which subtypes of patients with mesothelioma are most likely to benefit from immunotherapy?
-
2:00
checkmate 8hw: first-line nivolumab plus ipilimumab in msi-h/dmmr mcrc
-
4:11
mesothelioma data at asco 2020
-
26:27
top talk (ep 4) - checkmate 743: dual immunotherapy has significant survival benefit in mpm
-
0:40
beat-meso: phase iii trial of bevacizumab and chemo ± atezolizumab for advanced pleural mesothelioma
-
1:56
asco preview: mesothelioma
-
7:47
nivolumab & ipilimumab approved in europe for frontline unresectable malignant pleural mesothelioma